Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab

Immunomodulatory drugs hold promise for the management of cytokine release syndrome (CRS) in coronavirus disease-2019 (COVID-19) like tocilizumab (1, 2) However, its clinical utility in immunosuppressed patients is still lacking (3,4). Here, we describe the successful use of tocilizumab in a kidney transplant (KT) recipient with severe COVID-19.

Source: Kidney International - June 3, 2020 Category: Urology & Nephrology Authors: Gabriela Gautier-Vargas, Clement Baldacini, Ilies Benotmane, Nicolas Keller, Peggy Perrin, Bruno Moulin, Sophie Caillard Tags: letters to the editor Source Type: research